Gerhard Hager

Dr. Gerhard Hager is a serial entrepreneur and an expert in non-clinical research and development with a vast experience in the performance of preclinical programs for a wide range of drug candidate classes and therapeutic strategies. He is CEO of The NCD Company. He was Head of Toxicology at Baxter, Baxalta and Shire and has successfully overseen the development of a variety of products in different development stages, from drug discovery right to market approval at EMA, FDA and PMDA. Before that he was founder, scientific director and CEO of Aurigon and the Aurigon Group, an international non-clinical full-service research institute (CRO). He holds a PhD in Zoology from the LMU Munich and the Max-Planck-Institute of Psychiatry.

Dr. Hager supports Rationale Vaccines in the non-clinical development of his promising therapeutic HSV-2 vaccine candidate RVx201.